Russian oil spill may slide Dr Reddy's, Glenmark in Q3
This article was originally published in Scrip
The devaluation of the rouble is expected to hurt the fiscal Q3 earnings of a clutch of leading Indian firms, with the negative effect potentially spilling over into the fourth quarter as well, some analysts say.
You may also be interested in...
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."